These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


215 related items for PubMed ID: 19524477

  • 21. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ, Kulisevsky J.
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [Abstract] [Full Text] [Related]

  • 22. Hallucinations in Parkinson's disease: a follow-up study.
    de Maindreville AD, Fénelon G, Mahieux F.
    Mov Disord; 2005 Feb; 20(2):212-7. PubMed ID: 15390044
    [Abstract] [Full Text] [Related]

  • 23. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
    Devos D, French DUODOPA Study Group.
    Mov Disord; 2009 May 15; 24(7):993-1000. PubMed ID: 19253412
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Scaglione F, Fraschini F, Bergamasco B, Mauro A.
    Mov Disord; 2004 Aug 15; 19(8):937-42. PubMed ID: 15300660
    [Abstract] [Full Text] [Related]

  • 26. Apomorphine in patients with Parkinson's disease.
    Muguet D, Broussolle E, Chazot G.
    Biomed Pharmacother; 1995 Aug 15; 49(4):197-209. PubMed ID: 7669939
    [Abstract] [Full Text] [Related]

  • 27. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
    Garcia Ruiz PJ.
    Mov Disord; 2006 May 15; 21(5):727-8. PubMed ID: 16547919
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R.
    Mov Disord; 2006 Nov 15; 21(11):1899-907. PubMed ID: 16960863
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Effect of apomorphine on the bladder of parkinsonian patients].
    Aranda B, Cramer P, Adba MA.
    J Urol (Paris); 1992 Nov 15; 98(1):25-9. PubMed ID: 1527394
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 11.